WallStSmart

AstraZeneca PLC (AZN)vsKodiak Sciences Inc (KOD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

KOD

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 1/9Altman Z: -7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+13.9%)

Margin of Safety

+13.9%

Fair Value

$196.93

Current Price

$161.42

$35.51 discount

UndervaluedFair: $196.93Overvalued

Intrinsic value data unavailable for KOD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$263.09B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.7%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

KOD0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

KOD4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : KOD

KOD has a balanced fundamental profile.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.

Bear Case : KOD

The primary concerns for KOD are Revenue Growth, EPS Growth, Profit Margin.

Key Dynamics to Monitor

AZN profiles as a mature stock while KOD is a value play — different risk/reward profiles.

KOD carries more volatility with a beta of 2.21 — expect wider price swings.

AZN is growing revenue faster at 6.4% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (60/100 vs 25/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Kodiak Sciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.

Want to dig deeper into these stocks?